A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose and/or optimum biologic dose of MEDI-565 in adult
subjects and evaluate the safety profile in adult subjects with advanced gastrointestinal
adenocarcinomas who have no available standard or curative treatments.